{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T09:03:24Z","timestamp":1784711004772,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.canrad.2017.10.004","type":"journal-article","created":{"date-parts":[[2018,4,9]],"date-time":"2018-04-09T09:22:49Z","timestamp":1523265769000},"page":"222-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation at 3\u00a0years of concurrent bevacizumab and radiotherapy for breast cancer: Results of a prospective study"],"prefix":"10.1016","volume":"22","author":[{"given":"A.","family":"Dautruche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Belin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cottu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bontemps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lemanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"de la Lande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Missohou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"L\u00e9vy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Peignaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Reynaud-Bougnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gobillion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Pernin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2017.10.004_bib0125","first-page":"963","volume":"57","author":"Relf","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.canrad.2017.10.004_bib0130","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2017.10.004_bib0135","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-06-2441","article-title":"Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization","volume":"13","author":"Dings","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2017.10.004_bib0140","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1470-2045(13)70335-8","article-title":"Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial","volume":"14","author":"Cameron","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2017.10.004_bib0145","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(12)70049-9","article-title":"Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study","volume":"13","author":"Pierga","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2017.10.004_bib0150","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S1470-2045(16)00011-5","article-title":"Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study","volume":"17","author":"Bertucci","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2017.10.004_bib0155","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1158\/0008-5472.SABCS13-S1-03","article-title":"Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab\u00b1bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer","volume":"73","author":"Slamon","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.canrad.2017.10.004_bib0160","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2005.03.6780","article-title":"Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer","volume":"24","author":"Crane","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2017.10.004_bib0165","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1200\/JCO.2012.41.9820","article-title":"Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I\/II trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2017.10.004_bib0170","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ijrobp.2011.10.060","article-title":"A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417","volume":"83","author":"Schefter","year":"2012","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2017.10.004_bib0175","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.breast.2014.08.015","article-title":"Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer","volume":"23","author":"Pernin","year":"2014","journal-title":"Breast"},{"key":"10.1016\/j.canrad.2017.10.004_bib0180","doi-asserted-by":"crossref","first-page":"20140800","DOI":"10.1259\/bjr.20140800","article-title":"Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer","volume":"88","author":"Pernin","year":"2015","journal-title":"Br J Radiol"},{"key":"10.1016\/j.canrad.2017.10.004_bib0185","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0360-3016(79)90729-6","article-title":"Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast","volume":"5","author":"Harris","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.10.004_bib0190","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijrobp.2009.11.021","article-title":"Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab","volume":"79","author":"Goyal","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.10.004_bib0195","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clbc.2011.04.002","article-title":"Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer","volume":"11","author":"Yardley","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.canrad.2017.10.004_bib0200","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1186\/1471-2407-10-630","article-title":"Exclusive and adjuvant radiotherapy in breast cancer patients with synchronous metastases","volume":"10","author":"Le Scodan","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canrad.2017.10.004_bib0205","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S1470-2045(15)00135-7","article-title":"Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial","volume":"16","author":"Badwe","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2017.10.004_bib0210","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000360054","article-title":"Primary metastatic breast cancer: the impact of locoregional therapy","volume":"9","author":"Hartmann","year":"2014","journal-title":"Breast Care"},{"key":"10.1016\/j.canrad.2017.10.004_bib0215","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1200\/JCO.2008.19.5396","article-title":"Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy","volume":"27","author":"Le Scodan","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2017.10.004_bib0220","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1634\/theoncologist.2015-0106","volume":"20","author":"Landry","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.canrad.2017.10.004_bib0225","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12885-015-1053-z","article-title":"A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features","volume":"15","author":"Salazar","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canrad.2017.10.004_bib0230","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/annonc\/mdq736","article-title":"A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers","volume":"22","author":"Salama","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2017.10.004_bib0235","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijrobp.2010.02.030","article-title":"Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer","volume":"80","author":"Small","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.10.004_bib0240","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1093\/annonc\/mdu377","article-title":"Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study","volume":"25","author":"Borg","year":"2014","journal-title":"Ann Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321818300441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321818300441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:28:36Z","timestamp":1761136116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321818300441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1278321818300441"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2017.10.004","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation at 3\u00a0years of concurrent bevacizumab and radiotherapy for breast cancer: Results of a prospective study","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2017.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}